BiomX Inc.
For the period ended Jun 30, 2026. Filed Aug 19, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2026 · Filed Aug 19, 2026
HLSQ$0.07-37.4%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Interim Statements of Comprehensive Loss (unaudited)
UNAUDITED CONDENSED CONSOLIDATED INTERIM STATEMENTS OF COMPREHENSIVE LOSS
| Six months ended · Three months ended | ||||||
|---|---|---|---|---|---|---|
| June 30 · June 30 | ||||||
| 2026 · 2025 · 2026 · 2025 | ||||||
| Revenues | 332 | - | 332 | - | ||
| Cost of revenues | 235 | - | 235 | - | ||
| Gross profit | 97 | - | 97 | - | ||
| Operating expenses: | ||||||
| Research and development (“R&D”) expenses, net | (187) | 10,264 | 128 | 5,014 | ||
| General and administrative expenses | 6,994 | 4,925 | 5,383 | 2,419 | ||
| Operating loss | 6,710 | 15,189 | 5,414 | 7,433 | ||
| Other expenses (income) | (141) | 76 | 5 | 70 | ||
| Net gain from deconsolidation of subsidiary | (1,860) | - | - | - | ||
| Loss (income) from change in derivatives financial instruments measured at fair value | 12,458 | (2,412) | (1,598) | (1,498) | ||
| Interest expenses | 211 | 10 | 20 | 5 | ||
| Interest expense - related parties | 5 | - | 5 | - | ||
| Day one loss upon entering transaction | 5,226 | - | - | - | ||
| Finance expense, net | 377 | 830 | - | 25 | ||
| Net loss before tax | 22,986 | 13,693 | 3,846 | 6,035 | ||
| Tax expenses | - | 3 | - | 2 | ||
| Net loss | 22,986 | 13,696 | 3,846 | 6,037 | ||
| Net loss attributable to non-controlling interests | 74 | - | 74 | - | ||
| Net loss attributable to the Company’s stockholders | 22,912 | 13,696 | 3,772 | 6,037 | ||
| Net loss | 22,986 | 13,696 | 3,846 | 6,037 | ||
| Basic and diluted loss per share of Common Stock | 3.56 | 9.55 | (*) | 0.37 | 3.66 | (*) |
| Weighted average number of shares used in computing basic loss per share of Common Stock | 6,479,738 | 1,434,212 | (*) | 10,313,076 | 1,647,810 | (*) |
| Comprehensive loss: | ||||||
| Net loss | 22,986 | 13,696 | 3,846 | 6,037 | ||
| Other comprehensive income (loss) - Foreign currency translation adjustments | 7 | - | 7 | - | ||
| Comprehensive loss | 22,993 | 13,696 | 3,853 | 6,037 | ||
| Net - loss attributable to non-controlling interests | 74 | - | 74 | - | ||
| Other comprehensive income (loss) attributable to non-controlling interests -foreign currency translation adjustments | (14) | - | (14) | - | ||
| Comprehensive loss attributable to the Company’s stockholders | 23,053 | 13,696 | 3,913 | 6,037 | ||
| (*) | All share amounts have been retroactively adjusted to reflect a 1-for-19 reverse share split as discussed in Note 8A. |
|---|
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.